NASDAQ:MLND
Delisted
Millendo Therapeutics Inc. Stock News
$3.26
+0 (+0%)
At Close: Aug 17, 2022
Global Fertility Treatments Industry Report 2020 - Growth in the Median Age of First-time Motherhood is Driving Demand
05:00pm, Tuesday, 21'st Apr 2020
The "Fertility Treatments Market Global Report 2020-2030" report has been added to ResearchAndMarkets.com's offering.
Global Fertility Treatments Market Assessment 2020: Valued at $14.87 Billion in 2019 - ResearchAndMarkets.com
04:47pm, Friday, 17'th Apr 2020
The "Fertility Treatments Market Global Report 2020-2030" report has been added to ResearchAndMarkets.com's offering.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) * Forty Seven Inc (NASDAQ: FTSV) * Masimo Corporat
Xconomy: Millendo May Restructure After Prader-Willi Drug Fails Pivotal Test
10:42pm, Monday, 06'th Apr 2020
Millendo Therapeutics is considering a corporate reorganization after its lead drug, an investigational treatment for a rare genetic condition
Millendo Therapeutics (MLND) Gets a Hold Rating from Oppenheimer
08:17pm, Monday, 06'th Apr 2020
In a report released today,
Jay Olson
from Oppenheimer maintained a
Hold
rating on Millendo Therapeutics (
MLND
–
Research Report
), with a price target of
$2.00
. The company’s shares closed last
Millendo Therapeutics Announces Topline Results for Pivotal Phase 2b Study of Livoletide in Patients with Prader-Willi Syndrome (PWS)
Oppenheimer Maintains Their Buy Rating on Millendo Therapeutics (MLND)
08:38pm, Thursday, 19'th Mar 2020
In a report released today,
Jay Olson
from Oppenheimer maintained a
Buy
rating on Millendo Therapeutics (
MLND
–
Research Report
). The company’s shares closed last Monday at $6.10, close to its 5
Millendo Therapeutics (MLND) Gets a Buy Rating from Oppenheimer
11:49pm, Wednesday, 11'th Mar 2020
Oppenheimer analyst
Jay Olson
maintained a
Buy
rating on Millendo Therapeutics (
MLND
–
Research Report
) today and set a price target of
$25.00
. The company’s shares closed last Monday at $6.58,
Millendo Therapeutics Reports Full Year 2019 Operating and Financial Results
12:30pm, Wednesday, 11'th Mar 2020
Millendo Therapeutics Reports Full Year 2019 Operating and Financial Results
Millendo Therapeutics to Present at Upcoming Investor Conferences
01:30pm, Thursday, 05'th Mar 2020
Millendo Therapeutics to Present at Upcoming Investor Conferences
Spruce Bio Raises $88M for Clinical Tests of Rare Endocrine Disease Drug
03:59pm, Thursday, 20'th Feb 2020
Spruce Biosciences has raised $88 million to advance clinical testing of a drug for a rare inherited endocrine disorder that can lead to a potentially
Millendo’s Julia Owens on leadership in rare diseases -
09:26am, Thursday, 20'th Feb 2020
Rare disease specialists Millendo Therapeutics are hoping their drug livoletide will become the first treatment for Prader-Willi syndrome. Founder and CEO Julia Owens spoke to Paul Tunnah at JP Morgan
Millendo Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
01:30pm, Tuesday, 18'th Feb 2020
Millendo Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More
01:41pm, Friday, 14'th Feb 2020
Drugs typically go through three phases of clinical testing to support an application for FDA approval. It’s easy to overlook Phase 4, which takes place
Millendo Therapeutics Appoints Christophe Arbet-Engels, MD, PhD, as Chief Medical Officer
01:30pm, Monday, 10'th Feb 2020
Millendo Therapeutics appoints Christophe Arbet-Engels, MD, PhD, as Chief Medical Officer.
